The landscape of clinical trials for heavily pretreated multiple myeloma: opportunity for more randomization?

被引：0
|
作者：
Kapur, Rohan [1 ]
Mccarron, John [2 ]
Rajeeve, Sridevi [3 ]
Mohyuddin, Ghulam Rehman [4 ]
机构：
[1] Maimonides Hosp, Brooklyn, NY USA
[2] Univ Utah, Salt Lake City, UT USA
[3] Mem Sloan Kettering Canc Ctr, New York, NY USA
[4] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA
来源：
LEUKEMIA & LYMPHOMA | 2025年 / 66卷 / 02期
关键词：
THERAPY;
D O I：
10.1080/10428194.2024.2411625
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：355 / 357
页数：3
相关论文
共 50 条
  • [21] POMALIDOMIDE-DEXAMETHASONE IN THE MANAGEMENT OF HEAVILY PRETREATED MULTIPLE MYELOMA
    Cerchione, C.
    Nappi, D.
    Pareto, A. E.
    Migliaccio, I
    Zacheo, I
    Di Perna, M.
    Peluso, I
    Ferrara, K.
    Pane, F.
    Catalano, L.
    HAEMATOLOGICA, 2018, 103 : 39 - 39
  • [22] POMALIDOMIDE-DEXAMETHASONE IN THE MANAGEMENT OF HEAVILY PRETREATED MULTIPLE MYELOMA
    Cerchione, C.
    Catalano, L.
    Nappi, D.
    Pareto, A. E.
    Musuraca, G.
    Lucchesi, A.
    Ronconi, S.
    Ceccolini, M.
    Cangini, D.
    Giannini, M. B.
    Di Battista, V.
    Simonetti, G.
    Ferrari, A.
    Bochicchio, M. T.
    di Rora, A. Ghelli Luserna
    Ghetti, M.
    Napolitano, R.
    Fontana, M. C.
    Padella, A.
    Pane, F.
    Martinelli, G.
    HAEMATOLOGICA, 2020, 105 : S105 - S105
  • [23] Clinical trials for heavily pretreated patients: update in 2006
    Katlama, Christine
    Ghosn, Jade
    CURRENT OPINION IN HIV AND AIDS, 2006, 1 (06) : 495 - 501
  • [24] DOMESTIC OPPORTUNITY IN HEAVILY PRETREATED MULTIPLE MYELOMA NOT ELIGIBLE TO HOSPITAL-BASED TREATMENT: ROLE OF POMALIDOMIDE-DEXAMETHASONE
    Cerchione, C.
    Catalano, L.
    Nappi, D.
    Pareto, A. E.
    Musuraca, G.
    Lucchesi, A.
    Ronconi, S.
    Ceccolini, M.
    Cangini, D.
    Pane, F.
    Martinelli, G.
    HAEMATOLOGICA, 2022, 107 : 86 - 87
  • [25] Metronomic therapy for heavily pretreated relapsed/refractory multiple myeloma (RRMM).
    Papanikolaou, Xenofon
    Szymonifka, Jackie
    Mitchell, Alan
    Keller, Jason
    Heuck, Christoph Johann
    Waheed, Sarah
    Usmani, Saad Zafar
    Nair, Bijay
    Van Rhee, Frits
    Medlin, Stephen Charles
    Bailey, Clyde
    Petty, Nathan
    Hoering, Antje
    Crowley, John
    Barlogie, Bart
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [26] BENDAMUSTINE-BORTEZOMIB-DEXAMETHASONE (BVD) IN HEAVILY PRETREATED MULTIPLE MYELOMA
    Cerchione, C.
    Catalano, L.
    Nappi, D.
    Pareto, A. E.
    Basile, S.
    Marano, L.
    Peluso, I.
    Simeone, L.
    Vitagliano, O.
    Palmieri, S.
    Rocco, S.
    Ferrara, F.
    Pane, F.
    HAEMATOLOGICA, 2018, 103 : S86 - S86
  • [27] Symptomatic BK Virus Disease in Patients With Heavily Pretreated Multiple Myeloma
    Lebel, Eyal
    Chen, Christine
    Paul, Harminder
    Trudel, Suzanne
    Tiedemann, Rodger
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (06): : E506 - E509
  • [28] Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma
    Dimopoulos, Meletios-Athanasios
    Richardson, Paul
    Lonial, Sagar
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (07): : 460 - 473
  • [29] Selinexor, Bortezomib, and Dexamethasone for Heavily Pretreated Multiple Myeloma: A Case Series
    Magen, Hila
    Geva, Mika
    Volchik, Yulia
    Avigdor, Abraham
    Nagler, Arnon
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 (12): : E947 - E955
  • [30] The role of idecabtagene vicleucel in patients with heavily pretreated refractory multiple myeloma
    Oriol, Albert
    Abril, Laura
    Torrent, Anna
    Ibarra, Gladys
    Ribera, Josep-Maria
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2021, 12
12345